Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 06 June 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) on Tuesday announced that it is amending its regulations governing humanitarian device exemptions (HDE) to reflect changes brought on by the 21st Century Cures Act.
These exemptions provide a pathway for device makers looking to develop medical devices for small patient populations by exempting them from demonstrating a device's effectiveness.
Instead, a company must demonstrate that the humanitarian use device (HUD) "will not expose patients to an unreasonable or significant risk of illness or injury." Additionally, FDA restricts manufacturers from selling HUDs at a profit in most cases and limits their use to facilities with IRB oversight.
The changes are made in a final rule set to be published in the Federal Register on Wednesday, and are being issued without a notice and comment period as the changes in the final rule are in line with changes to the statute they implement.
Under the Cures Act, Congress increased the patient population threshold for HUDs from "fewer than 4,000" to "not more than 8,000." As such, FDA says it is amending its regulations to reflect that change.
FDA also is amending the requirements for institutional review board (IRB) oversight for humanitarian use devices to remove the requirement that the IRB overseeing their use be local, as stipulated by Cures.
This change reflects a shift in in the clinical landscape toward using a single or central IRB for multi-site studies.
Tags: Humanitarian Device Exemption, HDE, Humanitarian Use Device, HUD